Sugi Predict

Sugi Predict / Compounds / SCHEMBL570729

SCHEMBL570729

SCHEMBL570729

O=C(Cc1cccc(Br)c1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.54
▸ ERBB2 P04626 2/20 0.54
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ MAPT P10636 2/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ SRD5A2 P31213 2/20 0.50
▸ GLA P06280 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ MRGPRX4 Q96LA9 1/20 0.48
▸ PARP1 P09874 1/20 0.47
▸ PTPN1 P18031 1/20 0.47
▸ GSK3B P49841 1/20 0.47
▸ SIGMAR1 Q99720 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL931177 0.89 MAPT (0.57) EGFRERBB2NPC1RAB9AMAPT
SCHEMBL28392429 0.89 EGFR (0.54) EGFRERBB2MAPTL3MBTL1SRD5A2
Bromobenzene SCHEMBL27979945 0.87 MAPT (0.61) NPC1RAB9AMAPTL3MBTL1SRD5A2
SCHEMBL11633589 0.87 MAPT (0.60) NPC1RAB9AMAPTL3MBTL1SRD5A2
SCHEMBL27494960 0.85 EGFR (0.43) EGFRERBB2NPC1RAB9AMAPT
SCHEMBL4237046 0.83 NPC1 (0.54) NPC1RAB9AMAPTL3MBTL1GLA
SCHEMBL19659686 0.82 BCL2L1 (0.44) EGFRERBB2MAPTL3MBTL1SRD5A2
SCHEMBL13381372 0.81 SRD5A2 (0.62) RAB9AMAPTL3MBTL1SRD5A2KMT2A
SCHEMBL7475229 0.81 AKR1B1 (0.59) NPC1RAB9AMAPTL3MBTL1SRD5A2
SCHEMBL78652 0.81 AKR1B1 (0.58) EGFRERBB2MAPTSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815940-B2 Coumarin-chalcones as anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-08-26 — — US claimed
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 — — US claimed
EP-2601183-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS Council Of Scientific & Industrial Research (IN) 2013-06-12 — — EP claimed
WO-2012017454-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-02-09 — — WO claimed
US-20250188023-A1 BENZENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2025-06-12 — — US disclosed
US-12258308-B2 Benzene derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2025-03-25 — — US disclosed
US-20240198581-A2 Parallelized 3D Lithography Using Multi-Beam, Multi-Color Light-Induced Polymerization Karlsruher Institut für Technologie (DE) 2024-06-20 — — US disclosed
US-11999098-B2 Parallelized 3D lithography using multi-beam, multi-color light-induced polymerization Karlsruher Institut für Technologie (DE) 2024-06-04 — — US disclosed
CN-112513011-B Benzene derivatives 小野药品工业株式会社 2023-06-16 — — CN disclosed
US-20220089532-A1 BENZENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2022-03-24 — — US disclosed
US-11261154-B2 Benzene derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2022-03-01 — — US disclosed
US-20220055290-A1 Parallelized 3D Lithography Using Multi-Beam, Multi-Color Light-Induced Polymerization KARLSRUHER INST TECHNOLOGIE (DE) 2022-02-24 — — US disclosed
US-20180323379-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME HEESUNG MATERIAL LTD. (KR) 2018-11-08 — — US disclosed
US-8815940-B2 Coumarin-chalcones as anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-08-26 — — US disclosed
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 — — US disclosed
EP-2601183-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS Council Of Scientific & Industrial Research (IN) 2013-06-12 — — EP disclosed
WO-2012017454-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-02-09 — — WO disclosed
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 — — US disclosed
EP-1446110-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES Structural Bioinformatics Inc. (US) 2004-08-18 — — EP disclosed
WO-2003032916-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES STRUCTURAL BIOINFORMATICS INC. (US) 2003-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258308-B2 Benzene derivative PMP22, TMBIM6, MYT1 EGFR 4037/4885ERBB2 2854/4885NPC1 2638/4885
US-20180323379-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME CRY1, CRY2, PER2 EGFR 2941/4885ERBB2 2387/4885NPC1 4149/4885
US-11261154-B2 Benzene derivative PMP22, TMBIM6, MYT1 EGFR 4037/4885ERBB2 2854/4885NPC1 2638/4885
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases PTPRS, PTPRJ, PTPRCAP EGFR 1109/4885ERBB2 298/4885NPC1 4548/4885
US-20250188023-A1 BENZENE DERIVATIVE PMP22, TMBIM6, MYT1 EGFR 3968/4885ERBB2 2749/4885NPC1 2623/4885
US-20220089532-A1 BENZENE DERIVATIVE PMP22, TMBIM6, MYT1 EGFR 4037/4885ERBB2 2854/4885NPC1 2638/4885
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS HCCS, XPO5, CIAPIN1 EGFR 1055/4885ERBB2 1875/4885NPC1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.